Launching November 12, 2024
At Ambry, we understand the critical role genetic testing plays in tailored cancer treatment and proactive care. With our enhanced menu, you can deliver the clinical insights your patients need, backed by the exceptional support and patient access you expect from Ambry.
Evidence-Informed and Comprehensive
Our enhanced portfolio is informed by medical guidelines and the latest scientific evidence, with each test carefully curated by experts in gene-disease relationships. We are adding new indications and genes to support more comprehensive genetic assessment. For more information on Ambry’s approach to designing hereditary cancer tests, read this blog by Ambry Associate Director of Medical Science Liaisons, Jessica Grzybowski, MS, CGC.
Improved Flexibility and Ease-of-Use
We are introducing new add-on options to select tests so that you can choose whether to include limited evidence genes or pancreatitis genes. This will enable you to make informed test selections and tailor genetic testing to your patients' unique needs. We have also made it easier to order all cancer predisposition genes on the menu via CancerNext-Expanded®.
Streamlined
We are improving our pan-cancer multigene tests, CancerNext® and CancerNext-Expanded, and retiring select disease-specific tests. This is in response to the evolution of guidelines and clinician preference, as there is growing recognition that fewer hereditary cancer diagnoses are missed with pan-cancer tests, especially given known barriers in collecting complete, accurate family histories.1,2 For more information on this topic, read this blog by Ambry's Chief Medical Officer and Clinical Geneticist Dr. Elizabeth Chao.
+RNAinsight® for Unmatched Variant Detection & Classification
+RNAinsight®, paired DNA/RNA testing, remains available for order in combination with any genes on the hereditary cancer menu, with the exception of STAT testing and the STAT panel BRCAPlus®. For more information on how paired DNA and RNA can increase diagnostic yield, reduce variant of uncertain significance rate, and address longstanding evidence gaps in non-White populations, click here.
| Test Name | Test Code | Key Updates | Updated Gene Content |
|---|---|---|---|
| Test Name:
CancerNext® |
Test Code:8824 | Key Updates:• Aligned gene content with national consensus management guidelines • Added genes associated with adult renal cancer predisposition |
Updated Gene Content:
Adding: BAP1, FH, FLCN, MBD4, MET, TSC1, TSC2, VHL |
| CancerNext-Expanded® Up to 90 Genes |
8875 | • Aligned gene content with latest scientific evidence • Added several genes associated with adult leukemia predisposition • Now with two expertly curated add-on options: limited evidence genes and pancreatitis genes • Now can be used to order all cancer predisposition genes on the menu (instead of CustomNext-Cancer) |
Base Panel (76 genes): Adding: CEBPA, DDX41, ETV6, GATA2, MBD4, RUNX1, WT1 Removing: EGLN1, KIF1B Optional Add-Ons: Limited Evidence Genes (9 genes): ATRIP, EGLN1, KIF1B, MLH3, PALLD, RAD51B, RNF43, RPS20, TERT Pancreatitis Genes (5 genes): CFTR, CPA1, CTRC, PRSS1, SPINK1 |
| Test Name:BRCANext® Up to 26 Genes |
Test Code:8857 | Key Updates:• Base panel remains aligned with national consensus management guidelines • Now with optional expertly curated limited-evidence gene add-on |
Updated Gene Content:Base Panel (19 genes): No gene changes Limited Evidence Genes Add-On (7 genes): ATRIP, CDC73, FH, NTHL1, POLD1, POLE, RAD51B |
| ColoNext® Up to 26 Genes |
8821 | • Base panel gene content aligned with national consensus management guidelines • Now with optional expertly curated limited-evidence gene add-on |
Base Panel (20 genes): Adding MBD4, removing CHEK2 Limited Evidence Add-On (6 genes): ATM, CHEK2, CTNNA1, MLH3, RNF43, RPS20 |
| Test Name:CustomNext-Cancer® Select from 90 Genes |
Test Code:9511 | Key Updates:• Expertly curated gene content to choose from in unique clinical situations • No longer necessary to use CustomNext to order all genes on hereditary cancer menu (instead, order CancerNext-Expanded with both add-ons). |
Updated Gene Content:Adding: ATRIP, CEBPA, DDX41, ETV6, GATA2, MBD4, RAD51B, RNF43, RUNX1, WT1 Removing: BLM, CASR, FAM175A, FANCC, GALNT12, MRE11A, NBN, RAD50, RECQL, RINT1, XRCC2 |
Retired Tests
• BRCANext-Expanded®
• BrainTumorNext®
• MelanomaNext®
• PancNext®
• PancNext + Pancreatitis®
• PGLNext®
• ProstateNext®
• RenalNext®
What to Expect
Regardless of ordering method (AmbryPort, EHR integration, CARE, Progeny, or test requisition form), if a specimen is received 11/12/24 or later and:
• an updated test has been ordered: The updated gene content (i.e. new test version) will be reported. This includes CustomNext gene content.
• a retired product is ordered: An Ambry representative will notify you that the ordered test cannot be performed, and you will be advised to select an available test.
You should continue to experience the same test turnaround times and billing support you’ve come to expect from Ambry.Visit our website for the current menu offerings and test requisition form(s). These will be updated to reflect the new menu on November 12, 2024.
If you have questions, please contact your Ambry account executive. Your local genomic science liaison is available if clinical support would be helpful. You may also contact Client Solutions at (949) 900-5500, info@ambrygen.com, or via our Messages feature within AmbryPort.
___
1. Tung, N., Ricker, C., Messersmith, H., Balmaña, J., Domchek, S., Stoffel, E. M., Almhanna, K., Arun, B., Chavarri-Guerra, Y., Cohen, S. A., Cragun, D., Crew, K. D., Hall, M. J., Idos, G., Lopez, G., Pal, T., Pirzadeh-Miller, S., Pritchard, C., Rana, H. Q., Swami, U., … Vidal, G. A. (2024). Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 42(21), 2599–2615. https://doi.org/10.1200/JCO.24.00662
2. Welch, B. M., Wiley, K., Pflieger, L., Achiangia, R., Baker, K., Hughes-Halbert, C., Morrison, H., Schiffman, J., & Doerr, M. (2018). Review and Comparison of Electronic Patient-Facing Family Health History Tools. Journal of Genetic Counseling, 27(2), 381–391. https://doi.org/10.1007/s10897-018-0235-7
